M&A Deal Summary |
|
|---|---|
| Date | 2025-01-06 |
| Target | Predictive Oncology |
| Sector | Life Science |
| Buyer(s) | Renovaro Biosciences |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Sector | Life Science |
| Employees | 25 |
| Revenue | 19.6B USD (2023) |
Renovaro Biosciences has developed advanced cell, gene and immunotherapy platforms designed to renew the body's natural tumor-fighting capabilities against cancer and infectious diseases. Renovaro Biosciences is based in Los Angeles, California.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 4 |
| Sector: Life Science M&A | 3 of 4 |
| Type: Add-on Acquisition M&A Deals | 3 of 3 |
| State: Minnesota M&A | 1 of 1 |
| Country: United States M&A | 1 of 2 |
| Year: 2025 M&A | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-04-24 |
Cyclomics
Utrecht, Netherlands Cyclomics is a 4th generation multi-omics molecular biology company that offers accurate measurement of cancer recurrence using liquid biopsies. Cyclomics was formed in 2018 and is based in Utrecht, Netherlands. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-02-26 |
BioSymetrics
Huntington, New York, United States BioSymetrics is a AI-powered drug discovery and data analytics company, focusing on phenotype-based insights to identify novel therapeutics. BioSymetrics was founded in 2015 and is based in Huntington, New York. |
Buy | - |
